Literature DB >> 28890434

International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT).

Antoni Torres1,2, Michael S Niederman3,2, Jean Chastre4, Santiago Ewig5, Patricia Fernandez-Vandellos6, Hakan Hanberger7, Marin Kollef8, Gianluigi Li Bassi9, Carlos M Luna10, Ignacio Martin-Loeches11, J Artur Paiva12, Robert C Read13, David Rigau14, Jean François Timsit15, Tobias Welte16, Richard Wunderink17.   

Abstract

The most recent European guidelines and task force reports on hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) were published almost 10 years ago. Since then, further randomised clinical trials of HAP and VAP have been conducted and new information has become available. Studies of epidemiology, diagnosis, empiric treatment, response to treatment, new antibiotics or new forms of antibiotic administration and disease prevention have changed old paradigms. In addition, important differences between approaches in Europe and the USA have become apparent.The European Respiratory Society launched a project to develop new international guidelines for HAP and VAP. Other European societies, including the European Society of Intensive Care Medicine and the European Society of Clinical Microbiology and Infectious Diseases, were invited to participate and appointed their representatives. The Latin American Thoracic Association was also invited.A total of 15 experts and two methodologists made up the panel. Three experts from the USA were also invited (Michael S. Niederman, Marin Kollef and Richard Wunderink).Applying the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) methodology, the panel selected seven PICO (population-intervention-comparison-outcome) questions that generated a series of recommendations for HAP/VAP diagnosis, treatment and prevention.
Copyright ©ERS 2017.

Entities:  

Mesh:

Year:  2017        PMID: 28890434     DOI: 10.1183/13993003.00582-2017

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  214 in total

1.  Pulmonary Aspergillosis in Patients with Suspected Ventilator-associated Pneumonia in UK ICUs.

Authors:  Laura Loughlin; Thomas P Hellyer; P Lewis White; Danny F McAuley; Andrew Conway Morris; Raquel B Posso; Malcolm D Richardson; David W Denning; A John Simpson; Ronan McMullan
Journal:  Am J Respir Crit Care Med       Date:  2020-10-15       Impact factor: 21.405

2.  Pathogens and drug-resistance of hospital-acquired pneumonia in an EICU in Tianjin, China.

Authors:  Yanan Zhang; Songtao Shou
Journal:  Int J Biochem Mol Biol       Date:  2021-04-15

3.  Oral care with chlorhexidine: beware!

Authors:  Lila Bouadma; Michael Klompas
Journal:  Intensive Care Med       Date:  2018-05-28       Impact factor: 17.440

4.  Beat around the bush for VA-LRTI.

Authors:  Ignacio Martin-Loeches; Pieter Depuydt; Michael S Niederman
Journal:  Intensive Care Med       Date:  2018-10-21       Impact factor: 17.440

5.  M. pneumoniae and C. pneumoniae are no relevant pathogens in critically ill patients with hospital-acquired respiratory tract infections.

Authors:  Stefan Hagel; Svenja Schmitt; Miriam Kesselmeier; Michael Baier; Tobias Welte; Santiago Ewig; Mathias W Pletz
Journal:  Infection       Date:  2019-01-28       Impact factor: 3.553

6.  Short-Term Effects of Appropriate Empirical Antimicrobial Treatment with Ceftolozane/Tazobactam in a Swine Model of Nosocomial Pneumonia.

Authors:  Ana Motos; Gianluigi Li Bassi; Francesco Pagliara; Laia Fernandez-Barat; Hua Yang; Eli Aguilera Xiol; Tarek Senussi; Francesco A Idone; Chiara Travierso; Chiara Chiurazzi; Rosanel Amaro; Minlan Yang; Joaquim Bobi; Montserrat Rigol; David P Nicolau; Gerard Frigola; Roberto Cabrera; Jose Ramirez; Paolo Pelosi; Francesco Blasi; Massimo Antonelli; Antonio Artigas; Jordi Vila; Marin Kollef; Antoni Torres
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

7.  Time to Result for Pathogen Identification and Antimicrobial Susceptibility Testing of Bronchoalveolar Lavage and Endotracheal Aspirate Specimens in U.S. Acute Care Hospitals.

Authors:  Shawn H MacVane; Niels Oppermann; Romney M Humphries
Journal:  J Clin Microbiol       Date:  2020-10-21       Impact factor: 5.948

Review 8.  Ventilator-Associated Pneumonia: Diagnostic Test Stewardship and Relevance of Culturing Practices.

Authors:  Blaine Kenaa; Mary Elizabeth Richert; Kimberly C Claeys; Andrea Shipper; Kaede V Sullivan; Gregory M Schrank; Lyndsay M O'Hara; Daniel J Morgan; Carl Shanholtz; Surbhi Leekha
Journal:  Curr Infect Dis Rep       Date:  2019-11-21       Impact factor: 3.725

9.  Trimetoprim-sulfametoxazole in ventilator-associated pneumonia: a cohort study.

Authors:  Alessio Strazzulla; Maria Concetta Postorino; Anastasia Purcarea; Catherine Chakvetadze; Astrid de Farcy de Pontfarcy; Gianpiero Tebano; Aurelia Pitsch; Lyvan Vong; Sebastien Jochmans; Christophe Vinsonneau; Mehran Monchi; Sylvain Diamantis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-08-01       Impact factor: 3.267

Review 10.  Quality of smoking cessation advice in guidelines of tobacco-related diseases: An updated systematic review.

Authors:  Winifred Ekezie; Rachael L Murray; Sanjay Agrawal; Ilze Bogdanovica; John Britton; Jo Leonardi-Bee
Journal:  Clin Med (Lond)       Date:  2020-11       Impact factor: 2.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.